A method of preventing, reducing, or delaying the onset of fatty liver disease in a subject comprises enterally administering intact bovine milk-derived exosomes consisting of endogenous cargo to a subject in need thereof in an amount effective to reduce hepatic lipid accumulation. In a specific embodiment, the intact bovine milk-derived exosomes consisting of endogenous cargo can be administered in an amount effective to reduce de novo lipogenesis in the subject. The intact bovine milk-derived exosomes consisting of endogenous cargo can be administered to the subject directly or in a nutritional composition.

A method of obtaining an exosome-enriched product comprises providing a whey-containing bovine milk fraction, conducting a first centrifugation of the whey-containing bovine milk fraction to obtain a whey middle fraction, conducting a second centrifugation of the whey middle fraction at an increased speed to obtain a concentrated whey fraction, filtering the concentrated whey fraction to obtain a filtered whey fraction, and conducting a third centrifugation of the filtered whey fraction at a further increased speed to obtain an exosome-enriched product. The exosome-enriched product comprises intact exosomes and less than 5 wt % casein based on the total weight of protein in the exosome-enriched product. Nutritional compositions comprise protein, carbohydrate, and/or fat, and exosomes provided by addition of the exosome-enriched product. A method of improving insulin sensitivity in a subject comprises administering a nutritional composition comprising the exosome-enriched product.

This disclosure is directed to inhibitory oligonucleotides, inhibitory peptides, compositions and methods for preventing or treating Coronavirus disease 2019 (COVID-19). In one aspect, the disclosure is directed to compositions that comprise inhibitory oligonucleotides against one or more SARS-CoV-2 virus genes. In another aspect, the disclosure is directed to compositions that comprise inhibitory peptides that inhibit SARS-COV-2 entry into cells. Another aspect of the disclosure is directed to gene therapy methods for treating COVID-19, and vectors for carrying out the same. Finally, the disclosure provides nutritional supplements to support human immunity and prevent or inhibit viral infections.

The present invention belongs to the medical and technical field and provides a medicine or health food composition of nicotinamide mononucleotide and mogroside. In addition, the present invention also provides the preparation method, formulation and application of the composition.

The present invention belongs to the medical and technical field and provides a medicine or health food composition of nicotinamide mononucleotide and mogroside. In addition, the present invention also provides the preparation method, formulation and application of the composition.

A nutritional composition comprising miR-3126. miR-3126 or said nutritional composition for use as a medicament. Use of miR-3126 to modulate gene expression of one or more gene selected from: Ninein, Unc-13 homolog D, Sulfatase 2, IL-32, OXER1, TMEM127, Butyrophilin, Integrin subunit alpha 2, Integrin beta 1, tubulin alpha 4A, tubulin beta 6, tubulin beta 2A and tubulin beta 2B. A method of producing said nutritional composition.

A nutritional composition comprising miR-3126. miR-3126 or said nutritional composition for use as a medicament. Use of miR-3126 to modulate gene expression of one or more gene selected from: Ninein, Unc-13 homolog D, Sulfatase 2, IL-32, OXER1, TMEM127, Butyrophilin, Integrin subunit alpha 2, Integrin beta 1, tubulin alpha 4A, tubulin beta 6, tubulin beta 2A and tubulin beta 2B. A method of producing said nutritional composition.

A nutritional composition comprising miR-3184. miR-3184 or said nutritional composition for use as a medicament. Use of miR-3184 to modulate gene expression of one or more gene selected from Lipin 2 or Insulin Like Growth Factor 2. A method of producing said nutritional composition.

A nutritional composition comprising miR-3184. miR-3184 or said nutritional composition for use as a medicament. Use of miR-3184 to modulate gene expression of one or more gene selected from Lipin 2 or Insulin Like Growth Factor 2. A method of producing said nutritional composition.

This disclosure is directed to inhibitory oligonucleotides, inhibitory peptides, compositions and methods for preventing or treating Coronavirus disease 2019 (COVID-19). In one aspect, the disclosure is directed to compositions that comprise inhibitory oligonucleotides against one or more SARS-CoV-2 virus genes. In another aspect, the disclosure is directed to compositions that comprise inhibitory peptides that inhibit SARS-COV-2 entry into cells. Another aspect of the disclosure is directed to gene therapy methods for treating COVID-19, and vectors for carrying out the same. Finally, the disclosure provides nutritional supplements to support human immunity and prevent or inhibit viral infections.